Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 25 July, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Fundamental Analysis of Marksans Pharma Ltd

About the Company - Marksans Pharma Ltd

Marksans Pharma Ltd. is a Public Limited Listed company incorporated on 16/04/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24110MH1992PLC066364 and registration number is 066364. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 658.29 Cr. and Equity Capital is Rs. 40.93 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals11th Floor, Grandeur, Veera Desai Extension Road, Mumbai Maharashtra 400053companysecretary@marksanspharma.com
http://www.marksanspharma.com
Management
NamePosition Held
Mr. Mark SaldanhaChairman & Managing Director
Mrs. Sandra SaldanhaWhole Time Director
Mr. Seetharama R BuddharajuIndependent Director
Mr. Abhinna Sundar MohantyIndependent Director
Mr. Digant Mahesh ParikhIndependent Director
Mr. Varddhman V JainWhole Time Director
Mrs. Shailaja VardhanIndependent Director
Dr. Sunny SharmaNon Executive Director

Basic Stock Data of Marksans Pharma Ltd

Last Updated: July 24, 2024, 10:54 pm

Market Cap 9,294 Cr.
Current Price 205
High / Low208/93.8
Stock P/E29.6
Book Value 45.6
Dividend Yield0.24 %
ROCE20.6 %
ROE16.5 %
Face Value 1.00
PEG Ratio1.57

Data Source: screener.in

Competitors of Marksans Pharma Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Murae Organisor Ltd 36.3 Cr. 1.473.10/0.90727 2.260.00 %0.79 %0.13 % 2.00
Dipna Pharmachem Ltd 18.3 Cr. 7.6024.1/7.4616.8 15.60.00 %8.49 %4.47 % 10.0
Decipher Labs Ltd 18.5 Cr. 18.325.8/14.4 21.60.00 %4.30 %7.46 % 10.0
Coral Laboratories Ltd 250 Cr. 700748/24515.7 4970.00 %12.6 %9.58 % 10.0
Concord Drugs Ltd 38.4 Cr. 38.461.5/28.291.4 33.80.00 %4.54 %1.29 % 10.0
Industry Average21,561.64 Cr1,346.8661.02210.650.35%17.38%17.00%6.54

Marksans Pharma Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales356358330349361363418434453480486500531
Expenses273267235272301305354361372403376398417
Operating Profit83919577605864738077110102114
OPM %23%25%29%22%17%16%15%17%18%16%23%20%21%
Other Income4-36691215161418111019
Interest2231215232222
Depreciation199177921111413141418
Profit before tax6678977560605376787910497114
Tax %23%24%18%16%23%20%44%21%23%21%21%27%26%
Net Profit51598063464830606062837084
EPS in Rs1.241.441.941.531.111.180.691.461.511.571.811.521.84

Last Updated: July 10, 2024, 7:34 pm

Marksans Pharma Ltd Quarterly Chart

Marksans Pharma Ltd Profit & Loss

Last Updated: July 10, 2024, 7:34 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales3564386307978937679131,0001,1341,3761,4911,8522,103
Expenses4553695126127577228348689421,0371,2321,5131,645
Operating Profit-100691181851364578132192340259340458
OPM %-28%16%19%23%15%6%9%13%17%25%17%18%22%
Other Income2443978507425945
Interest54151916107101098899
Depreciation24161616283027232736455267
Profit before tax-17544861561071550104157302248338427
Tax %-1%-12%15%28%23%24%28%23%23%21%25%21%
Net Profit-176497411283113680121239187265320
EPS in Rs1.191.872.671.920.220.801.872.955.834.515.887.01
Dividend Payout %-0%10%5%4%21%23%6%3%3%4%6%9%

Marksans Pharma Ltd Profit & Loss Yearly Chart

Marksans Pharma Ltd Growth

Compounded Sales Growth
10 Years:13%
5 Years:17%
3 Years:17%
TTM:18%
Compounded Profit Growth
10 Years:16%
5 Years:33%
3 Years:10%
TTM:18%
Stock Price CAGR
10 Years:20%
5 Years:67%
3 Years:34%
1 Year:77%
Return on Equity
10 Years:18%
5 Years:20%
3 Years:18%
Last Year:16%

Last Updated: July 24, 2024, 5:24 pm

Marksans Pharma Ltd Balance Sheet

Last Updated: July 10, 2024, 7:34 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital37393941414141414141414545
Reserves-22034903264013924305025958461,0681,7001,830
Preference Capital1414141212-0-0-0-0-0-0-0
Borrowings17916316089881101181003034111123111
Other Liabilities389165202220192209142160236307416322327
Total Liabilities3854014906767227527318029021,2271,6362,1902,314
Fixed Assets165156146166270267279270303309428486560
CWIP-0-0-0-0-00-0-0-01231019
Investments-0-0-0-0-0-0-0-0-0-0011
Other Assets2202453445104524844515335999061,2051,6941,734
Total Assets3854014906767227527318029021,2271,6362,1902,314

Marksans Pharma Ltd Reserves and Borrowings Chart

Marksans Pharma Ltd Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity 39651553114502723317999237230
Cash from Investing Activity -5-4-33-123-21-39-13-60-45-84-259-141
Cash from Financing Activity -40-2917-58-33-21-114-1580198-69
Net Cash Flow-731138-150-1015-7601189417621

Marksans Pharma Ltd Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days10998848911871647872978276
Inventory Days112102107120151152215155248216192217
Days Payable818388851295478711031029194
Cash Conversion Cycle141118103124140169202163217211183199
Working Capital Days3748559513011713394110138133143
ROCE %43%37%44%23%4%10%18%25%38%23%22%

Marksans Pharma Ltd Financial Efficiency Indicators Chart

Marksans Pharma Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Promoters48.25%48.25%48.25%48.25%48.25%48.25%48.25%48.60%49.00%43.85%43.85%43.85%
FIIs5.05%4.34%3.14%2.64%2.59%3.46%4.04%4.06%4.23%15.11%14.90%15.07%
DIIs0.30%0.34%0.56%0.53%0.41%0.47%0.94%0.95%0.96%1.46%3.65%4.02%
Public46.40%47.07%48.05%48.58%48.75%47.82%46.77%46.38%45.79%39.57%37.60%37.06%
No. of Shareholders1,30,1161,35,2711,88,8882,01,4512,14,9982,20,0902,21,3592,17,7432,13,1231,98,3821,88,4472,07,937

Marksans Pharma Ltd Shareholding Pattern Chart

No. of Marksans Pharma Ltd Shareholders

Marksans Pharma Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Small Cap Fund12,641,2591.88210.29225,7772024-07-235499%
UTI Aggressive Hybrid Fund2,078,2530.4621.94225,7772024-07-23820.49%
UTI Large & Mid Cap Fund1,082,6110.5811.43225,7772024-07-23379.5%
UTI Retirement Fund1,049,4990.2811.08225,7772024-07-23364.84%
Motilal Oswal Nifty Microcap 250 Index Fund225,7770.663.76225,7772024-07-230%
UTI Healthcare Fund232,7110.322.46225,7772024-07-233.07%
Motilal Oswal S&P BSE Healthcare ETF2,6910.490.04225,7772024-07-23-98.81%
Groww Nifty Total Market Index Fund5570.020.01225,7772024-07-23-99.75%

Marksans Pharma Ltd ROCE Trend

Marksans Pharma Ltd EPS Trend

Marksans Pharma Ltd Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)6.926.414.515.762.86
Diluted EPS (Rs.)6.926.414.515.762.86
Cash EPS (Rs.)8.597.005.666.713.60
Book Value[Excl.RevalReserv]/Share (Rs.)46.0338.9529.8822.1215.86
Book Value[Incl.RevalReserv]/Share (Rs.)46.0338.9529.8822.1215.86
Revenue From Operations / Share (Rs.)48.0540.8736.4233.6227.71
PBDIT / Share (Rs.)11.238.807.358.464.70
PBIT / Share (Rs.)9.597.656.257.584.05
PBT / Share (Rs.)9.357.456.057.383.84
Net Profit / Share (Rs.)6.955.854.565.832.95
NP After MI And SOA / Share (Rs.)6.925.884.565.832.95
PBDIT Margin (%)23.3721.5220.1725.1616.97
PBIT Margin (%)19.9618.7217.1622.5314.62
PBT Margin (%)19.4518.2316.6021.9513.85
Net Profit Margin (%)14.4614.3212.5317.3310.64
NP After MI And SOA Margin (%)14.4014.3712.5317.3310.64
Return on Networth / Equity (%)15.1915.2515.5326.9018.98
Return on Capital Employeed (%)18.9718.7519.9333.3524.62
Return On Assets (%)11.7012.1511.3919.4213.37
Total Debt / Equity (X)0.010.020.030.020.02
Asset Turnover Ratio (%)0.890.961.040.730.61
Current Ratio (X)4.784.913.373.022.59
Quick Ratio (X)3.193.492.181.671.54
Inventory Turnover Ratio (X)1.211.351.301.741.14
Dividend Payout Ratio (NP) (%)0.003.815.471.7124.43
Dividend Payout Ratio (CP) (%)0.003.194.411.4920.01
Earning Retention Ratio (%)0.0096.1994.5398.2975.57
Cash Earning Retention Ratio (%)0.0096.8195.5998.5179.99
Interest Coverage Ratio (X)45.4343.6735.6143.3622.02
Interest Coverage Ratio (Post Tax) (X)29.1130.0723.1230.8714.81
Enterprise Value (Cr.)6244.012540.861577.141869.83507.17
EV / Net Operating Revenue (X)2.871.371.061.360.44
EV / EBITDA (X)12.276.375.245.402.63
MarketCap / Net Operating Revenue (X)3.151.721.251.490.50
Retention Ratios (%)0.0096.1894.5298.2875.56
Price / BV (X)3.331.831.552.310.89
Price / Net Operating Revenue (X)3.151.721.251.490.50
EarningsYield0.040.080.100.110.21

Marksans Pharma Ltd Profitability Ratios (%)

Marksans Pharma Ltd Liquidity Ratios

Marksans Pharma Ltd Liquidity Ratios (%)

Marksans Pharma Ltd Interest Coverage Ratios (%)

Marksans Pharma Ltd Valuation Ratios

Fair Value

Fair Value: 223.24

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 8.90% compared to the current price 205

Intrinsic Value: 265.44

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 29.48% compared to the current price 205

Last 5 Year EPS CAGR: 18.90%

*Investments are subject to market risks

Strength and Weakness of Marksans Pharma Ltd Stock

StrengthWeakness
  1. The stock has a high average ROCE of 23.92%, which is a positive sign.
  2. The company has higher reserves (700.33 cr) compared to borrowings (118.33 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (369.31 cr) and profit (143.00 cr) over the years.
  1. The stock has a high average Working Capital Days of 102.75, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 164.17, which may not be favorable.

FAQ

What is the latest fair value of Marksans Pharma Ltd?

The latest fair value of Marksans Pharma Ltd is ₹223.24.

What is the Market Cap of Marksans Pharma Ltd?

The Market Cap of Marksans Pharma Ltd is 9,294 Cr..

What is the current Stock Price of Marksans Pharma Ltd as on 25 July 2024?

The current stock price of Marksans Pharma Ltd as on 25 July 2024 is 205.

What is the High / Low of Marksans Pharma Ltd stocks in FY 2024?

In FY 2024, the High / Low of Marksans Pharma Ltd stocks is 208/93.8.

What is the Stock P/E of Marksans Pharma Ltd?

The Stock P/E of Marksans Pharma Ltd is 29.6.

What is the Book Value of Marksans Pharma Ltd?

The Book Value of Marksans Pharma Ltd is 45.6.

What is the Dividend Yield of Marksans Pharma Ltd?

The Dividend Yield of Marksans Pharma Ltd is 0.24 %.

What is the ROCE of Marksans Pharma Ltd?

The ROCE of Marksans Pharma Ltd is 20.6 %.

What is the ROE of Marksans Pharma Ltd?

The ROE of Marksans Pharma Ltd is 16.5 %.

What is the Face Value of Marksans Pharma Ltd?

The Face Value of Marksans Pharma Ltd is 1.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Marksans Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE